Exicure (XCUR) Competitors $5.92 -0.18 (-2.87%) Closing price 03:58 PM EasternExtended Trading$5.92 -0.01 (-0.17%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. CTOR, CTMX, EDIT, TLSA, TIL, FDMT, OGI, SLN, SLS, and CYBNShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Citius Oncology (CTOR), CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Tiziana Life Sciences (TLSA), Instil Bio (TIL), 4D Molecular Therapeutics (FDMT), Organigram Global (OGI), Silence Therapeutics (SLN), Galena Biopharma (SLS), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Citius Oncology CytomX Therapeutics Editas Medicine Tiziana Life Sciences Instil Bio 4D Molecular Therapeutics Organigram Global Silence Therapeutics Galena Biopharma Cybin Citius Oncology (NASDAQ:CTOR) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Which has preferable valuation & earnings, CTOR or XCUR? Citius Oncology has higher earnings, but lower revenue than Exicure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/AExicure$500K74.89-$9.70M-$4.81-1.23 Do institutionals and insiders hold more shares of CTOR or XCUR? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by insiders. Comparatively, 8.4% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer CTOR or XCUR? Citius Oncology currently has a consensus target price of $3.00, suggesting a potential downside of 43.03%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Citius Oncology is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, CTOR or XCUR? Citius Oncology has a beta of 2.95, suggesting that its share price is 195% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.58, suggesting that its share price is 258% more volatile than the S&P 500. Does the media refer more to CTOR or XCUR? In the previous week, Citius Oncology and Citius Oncology both had 5 articles in the media. Exicure's average media sentiment score of 0.57 beat Citius Oncology's score of 0.38 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is CTOR or XCUR more profitable? Citius Oncology's return on equity of -53.88% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -53.88% -18.86% Exicure N/A -353.47%-96.50% SummaryCitius Oncology beats Exicure on 5 of the 9 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.45M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-1.5521.2626.2019.89Price / Sales74.89279.34415.50166.23Price / CashN/A41.8936.4957.06Price / Book5.297.508.055.39Net Income-$9.70M-$55.05M$3.15B$248.50M7 Day Performance1.20%2.49%1.92%2.96%1 Month Performance-43.36%7.40%4.90%6.02%1 Year Performance1,810.06%5.42%35.95%20.44% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.9836 of 5 stars$5.93-2.9%N/A+1,835.9%$37.45M$500K-1.5550Earnings ReportGap DownCTORCitius Oncology0.3647 of 5 stars$2.50-4.9%$3.00+20.0%N/A$188.18MN/A0.00N/AGap DownCTMXCytomX Therapeutics4.2989 of 5 stars$2.16-6.9%$5.33+146.9%+77.4%$187.04M$138.10M4.50170Positive NewsEDITEditas Medicine4.2757 of 5 stars$2.10-5.4%$4.70+123.8%-51.2%$185.84M$32.31M-0.69230TLSATiziana Life Sciences1.4496 of 5 stars$1.55-0.6%N/A+75.0%$182.28MN/A0.008TILInstil Bio3.3832 of 5 stars$29.84+7.7%$119.00+298.8%+112.9%$181.68MN/A-2.49410Gap UpFDMT4D Molecular Therapeutics2.3021 of 5 stars$3.77-8.7%$29.56+684.0%-80.6%$174.65M$23K-1.19120OGIOrganigram Global1.1602 of 5 stars$1.28-0.8%N/A-14.3%$172.78M$117.47M12.80860SLNSilence Therapeutics2.8716 of 5 stars$5.77-3.0%$33.83+486.4%-68.4%$172.70M$27.70M-3.85100SLSGalena Biopharma0.7462 of 5 stars$1.71+11.0%N/A+76.3%$170.62M$1M-4.5010Positive NewsHigh Trading VolumeCYBNCybin2.6209 of 5 stars$7.41-4.8%$86.00+1,060.6%N/A$170.39MN/A-1.6950 Related Companies and Tools Related Companies Citius Oncology Alternatives CytomX Therapeutics Alternatives Editas Medicine Alternatives Tiziana Life Sciences Alternatives Instil Bio Alternatives 4D Molecular Therapeutics Alternatives Organigram Global Alternatives Silence Therapeutics Alternatives Galena Biopharma Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
